Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen    BIIB

BIOGEN (BIIB)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Biogen Idec Inc. : Biogen 4th-Quarter Profit Falls 2.7% on Higher Costs; Revenue Up

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/28/2013 | 01:13pm CEST
   By Tess Stynes and Melodie Warner 
 

Biogen Idec Inc.'s (BIIB) fourth-quarter earnings fell 2.7% as the biotechnology company's efforts to bulk up its product pipeline masked its revenue growth.

The company also forecast 2013 adjusted earnings of $7.15 to $7.25 a share on about 10% revenue growth. Analysts surveyed by Thomson Reuters expect $7.27 a share on a 9% rise in revenue to $5.98 billion.

Biogen on Thursday said a new version of its blockbuster multiple-sclerosis drug Avonex was successful in a late-stage trial, strengthening the company's stable of drugs for the degenerative nerve disease. However, the overall market for such injectable drugs is expected to decline sharply amid a growing market for oral-pill-based drugs. Biogen's own BG-12 pill could be approved and launched in the U.S. as soon as March.

Biogen has been beefing up its sales force and readying its manufacturing supply chain as some drugs in its late-stage product pipeline have been drawing closer to entering the market.

Research and development costs rose 1.8% in the latest period while selling, general and administrative costs jumped 32%.

Biogen reported a profit of $292.1 million, or $1.23 a share, down from $300.2 million, or $1.22 a share, a year earlier. Excluding items such as stock-option expense, amortization and restructuring charges, per-share earnings fell to $1.40 from $1.51. Revenue increased 6.9% to $1.42 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.46 a share on revenue of $1.39 billion.

In the latest quarter, sales of Avonex rose 7.1% to $753.2 million.

Shares closed Friday at $146.20 and were inactive premarket. The stock is up 23% over the past year.

Write to Tess Stynes at [email protected] and Melodie Warner at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOGEN
04/20BIOGEN : Builds on Its 40-Year Legacy in Neuroscience with Presentation of Resea..
AQ
04/17BIOGEN : Builds on Its 40-Year Legacy in Neuroscience with Presentation of Resea..
BU
04/12BIOGEN : and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercial..
AQ
04/10BIOGEN : and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercial..
AQ
04/05NEW ANTIBODIES FINDINGS FROM BIOGEN : Relation to Cell Growth and Specific Prod..
AQ
04/05BIOGEN : to Report First Quarter 2018 Financial Results on April 24, 2018
AQ
04/05Samsung, Biogen Reach Deal With AbbVie to Sell Near Copy of Humira
DJ
04/05BIOGEN : and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercial..
BU
04/02BIOGEN : to Report First Quarter 2018 Financial Results on April 24, 2018
AQ
03/28BIOGEN : to Report First Quarter 2018 Financial Results on April 24, 2018
BU
More news
News from SeekingAlpha
09:30aSTOCKS TO WATCH : Earnings Blockbusters And Trump Talks Drug Prices 
04/20Key events next week - healthcare 
04/20Ionis up 8% premarket on new $1B 10-year collaboration with Biogen in neurolo.. 
04/20IONIS : Cash, Catalysts And More 
04/16vTv Therapeutics Fails Late-Stage Alzheimer's Study; Is There A Chance For A .. 
Financials ($)
Sales 2018 12 975 M
EBIT 2018 6 962 M
Net income 2018 4 558 M
Debt 2018 422 M
Yield 2018 -
P/E ratio 2018 12,02
P/E ratio 2019 11,34
EV / Sales 2018 4,32x
EV / Sales 2019 3,77x
Capitalization 55 645 M
Chart BIOGEN
Duration : Period :
Biogen Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Technical analysis trends BIOGEN
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 372 $
Spread / Average Target 41%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Alisha A. Alaimo Senior Vice President-US Therapeutic Operations
Jeffrey D. Capello Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN-17.44%55 645
CSL LIMITED13.09%55 896
ALEXION PHARMACEUTICALS-6.56%23 966
GRIFOLS-4.16%17 743
BIOMARIN PHARMACEUTICAL-6.22%14 491
WUXI BIOLOGICS CAYMAN INC--.--%11 328